Deyan Yosifov
Deyan Yosifov
Няма данни за членство
Потвърден имейл адрес: uniklinik-ulm.de - Начална страница
Заглавие
Позовавания
Позовавания
Година
Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues
BS Hanna, PM Roessner, H Yazdanparast, D Colomer, E Campo, ...
Leukemia 33 (3), 625-637, 2019
462019
Erucylphospho-N, N, N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity
DY Yosifov, PT Todorov, MM Zaharieva, KD Georgiev, BA Pilicheva, ...
Cancer chemotherapy and pharmacology 67 (1), 13-25, 2011
332011
FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL
V Close, W Close, SJ Kugler, M Reichenzeller, DY Yosifov, J Bloehdorn, ...
Blood, The Journal of the American Society of Hematology 133 (8), 830-839, 2019
312019
From biology to therapy: the CLL success story
DY Yosifov, C Wolf, S Stilgenbauer, D Mertens
HemaSphere 3 (2), 2019
262019
Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell lines
DY Yosifov, KA Kaloyanov, ML Guenova, K Prisadashka, MB Balabanova, ...
Leukemia research 38 (1), 49-56, 2014
192014
Erucylphospho-N,N,N-trimethylpropylammonium shows substantial cytotoxicity in multiple myeloma cells
DY Yosifov, SM Konstantinov, MR Berger
Natural Compounds and Their Role in Apoptotic Cell Signaling Pathways 1171 …, 2009
18*2009
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1
E Tausch, P Beck, RF Schlenk, BMC Jebaraj, A Dolnik, DY Yosifov, ...
haematologica 105 (10), 2020
132020
Interleukin-6, osteopontin and Raf/MEK/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholines
DY Yosifov, C Reufsteck, SM Konstantinov, MR Berger
Leukemia research 36 (6), 764-772, 2012
102012
Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL
DY Yosifov, I Idler, N Bhattacharya, M Reichenzeller, V Close, D Ezerina, ...
Leukemia 34 (1), 115-127, 2020
92020
Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany)
Y Ilieva, K Kaloyanov, D Yosifov, B Robev, I Zhelezova, M Genova, ...
Phytochemistry Reviews 13 (2), 459-469, 2014
82014
The expression level of the tumor suppressor retinoblastoma protein (Rb) influences the antileukemic efficacy of erucylphospho-N, N, N-trimethylpropylammonium (ErPC3)
DY Yosifov, IK Dineva, MM Zaharieva, SM Konstantinov, MR Berger
Cancer biology & therapy 6 (6), 930-935, 2007
82007
Cytotoxicity of gypsogenic acid isolated from Gypsophila trichotoma
I Krasteva, M Yotova, D Yosifov, N Benbassat, K Jenett-Siems, ...
Pharmacognosy magazine 10 (Suppl 2), S430, 2014
42014
A particular expression pattern of CD13 epitope 7H5 in chronic lymphocytic leukaemia - a possible new therapeutic target
ML Guenova, A Michova, GN Balatzenko, DY Yosifov, N Stoyanov, ...
Hematology 17 (3), 132-139, 2012
42012
DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy
DY Yosifov, J Bloehdorn, H Döhner, P Lichter, S Stilgenbauer, D Mertens
Scientific data 7 (1), 1-10, 2020
12020
Minor mutations in TP53 associate with shorter PFS but not OS after chemoimmunotherapy-Results from the Complement2 trial
E Tausch, D Yosifov, N Massoudy-Touiserkan, A Dolnik, B Jebaraj, ...
LEUKEMIA & LYMPHOMA 61, 141-143, 2020
12020
NOTCH1 signaling is activated in CLL by mutations of FBXW7 and low expression of USP28 at 11q23
V Close, W Close, SJ Kugler, M Reichenzeller, DY Yosifov, J Bloehdorn, ...
Blood 132, 946, 2018
12018
GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PLUS EITHER CHLORAMBUCIL OR VENETOCLAX‐UPDATED ANALYSIS OF THE CLL14 TRIAL
E Tausch, C Schneider, D Yosifov, S Robrecht, C Zhang, O Al‐Sawaf, ...
Hematological Oncology 39, 2021
2021
A dataset of sequential DnA methylation profiles (2 timepoints) of 10 patients with chronic lymphocytic leukemia
D Yosifov, E Tausch, D Mertens
Universität Ulm, 2021
2021
Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo (immune) therapy
M Zapatka, E Tausch, S Öztürk, DY Yosifov, M Seiffert, T Zenz, ...
Haematologica, 2020
2020
Genome-wide analysis of impact of culture conditions on gene expression of primary leukemic cells from chronic lymphocytic leukemia (cll)
D Yosifov, I Idler, N Bhattacharya, M Reichenzeller, V Meyer-Pannwitt, ...
Universität Ulm, 2019
2019
Системата не може да изпълни операцията сега. Опитайте отново по-късно.
Статии 1–20